Please wait

Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Apellis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
     Security
Type		   Security
Class
Title		   Fee
Calculation
or Carry
Forward
Rule		   Amount
Registered		   Proposed
Maximum
Offering
Price Per
Unit		   Maximum
Aggregate
Offering
Price		   Fee
Rate		   Amount of
Registration
Fee		   Carry
Forward
Form
Type		   Carry
Forward
File
Number		   Carry
Forward
Initial
Effective
Date		   Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward
 
Newly Registered Securities
                         
Fees to Be
Paid		   Equity   Common Stock, par value $0.0001 per share   457(r)   (1)   (1)   (1)   (2)   (2)     —   —   —   —
                         
Fees to Be
Paid		   Equity   Preferred Stock   457(r)   (1)   (1)   (1)   (2)   (2)     —   —   —   —
                         
Fees to Be
Paid		   Debt   Debt Securities   457(r)   (1)   (1)   (1)   (2)   (2)     —   —   —   —
                         
Fees to Be
Paid		   Equity   Warrants   457(r)   (1)   (1)   (1)   (2)   (2)     —   —   —   —
                         
Fees to Be
Paid		   Equity   Units (3)   457(r)   (1)   (1)   (1)   (2)   (2)     —   —   —   —
                         
Fees
Previously
Paid		   —   —   —     —   —     —     —   —   —   —
 
Carry Forward Securities
                         
Carry
Forward
Securities		   —   —   —     —   —     —     —   —   —   —
                   
    Total Offering Amounts      $                $             —           
                   
    Total Fees Previously Paid          $             —           
                   
    Total Fee Offsets          $27,810 (4)           
                   
    Net Fee Due                $             —                 

Table 2: Fee Offset Claims and Sources

 

                       
     Registrant
or Filer
Name		   Form
or
Filing
Type		   File
Number		   Initial
Filing
Date		   Filing
Date		   Fee Offset
Claimed		   Security
Type
Associated
with Fee
Offset
Claimed		   Security
Title
Associated
with Fee
Offset
Claimed		   Unsold
Securities
Associated
with Fee
Offset
Claimed		   Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset
Claimed		   Fee Paid
with Fee
Offset
Source
 
Rule 457(p)
                       

Fee Offset
Claims

   Apellis Therapeutics, Inc.   S-3   333-235830   January 7, 2020      $27,810   Unallocated (Universal) Shelf   (4)   (4)   $300,000,000    —
                       
Fee Offset
Sources		   Apellis Therapeutics, Inc.   S-3   333-235830   —   January 7, 2020    —   —   —   —   —   $(2)

 

(1)

Pursuant to Instruction 2.A(iii)(c) of Item 16(b) of Form S-3, this information is not required to be included. An indeterminate amount of the securities of each identified class is being registered as may from time to time be offered under this registration statement at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold under this registration statement. Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.

(2)

In accordance with Rule 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of all registration fees other than the registration fee due in connection with the shares of common stock that may be issued and sold from time to time under the sale agreement prospectus included in this registration statement. Any subsequent registration fees will be paid on a pay-as-you-go basis.

(3)

Units may be issued under a unit agreement and will represent an interest in one or more securities registered under this registration statement including shares of common stock or preferred stock, debt securities or warrants, in any combination, which may or may not be separable from one another.

(4)

On January 7, 2020, the registrant filed a registration statement on Form S-3 (File No. 333-235830), or the Prior Registration Statement, registering an indeterminate amount of securities. As of the date of this registration statement, the registrant registered an aggregate of $1,527,225,010 of securities, representing $154,901.91 in registration fees, and sold $1,227,225,010 of such securities, representing $127,091.91 in registration fees under the Prior Registration Statement, leaving the balance of $300,000,000 of unsold securities, representing $27,810 in registration fees, of such unsold securities under the Prior Registration Statement. All offerings under the Prior Registration Statement have been terminated or completed. Pursuant to Rule 457(p) under the Securities Act, the unused fees of $27,810 that have already been paid and remains unused with respect to securities that were previously registered pursuant to the Prior Registration Statement and were not sold thereunder will be applied to the fees payable pursuant to this registration statement under the applicable prospectus supplement.